Small leucine-rich protein 1 (SMLR1)

Small leucine-rich protein 1 is a transmembrane protein of 107 amino acids in humans, predominantly expressed in the liver and small intestine[1][3][5]. It localizes to the endoplasmic reticulum and cis-Golgi complex in hepatocytes, suggesting a role in trafficking of very low-density lipoprotein (VLDL) particles from the ER to the Golgi[1][3]. Loss of SMLR1 expression in the liver results in hepatic steatosis (fat accumulation) and susceptibility to NASH, but also leads to reduced plasma triglycerides and apolipoprotein B, reduced VLDL secretion, and protection against dietary atherosclerosis in mice[1][3]. There is no evidence SMLR1 is a classic molecular therapeutic target (i.e., receptor or enzyme), nor are there any drugs known to modulate its activity at this time[1][3][5]. Its molecular function is still under investigation, and it is not grouped with the canonical small leucine-rich repeat proteoglycan (SLRP) family members like decorin or biglycan[2][4][6].

Other names

small leucine-rich protein 1SMLR1